Last reviewed · How we verify
COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine
Approved treatments
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine patent landscape — cliff calendar, originator estates, attackable patents
- COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine treatment landscape brief
- COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine treatment updates RSS
Frequently asked questions about COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine
What drugs treat COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine?
Tracked treatments include BNT162b6 Bivalent (Original/OMI BA.4/BA.5).
What is the treatment for COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine?
Standard treatment for COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine includes BNT162b6 Bivalent (Original/OMI BA.4/BA.5). See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine patent cliff · COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine CI report
- Treatment: BNT162b6 Bivalent (Original/OMI BA.4/BA.5) · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing